Zafirlukast Improves Pulmonary Function in Patients with Moderate Persistent Asthma Receiving Regular Inhaled Steroids: A Prospective Randomized Control Study

Chung Jen Huang, Chun Hua Wang, Wen Te Liu, Mei Chen Yang, Horng Chyuan Lin, Chih Teng Yu, Chia Jung Shiao, Chia Chun Tan, Chao Kai Yang, Han Pin Kuo

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Zafirlukast is a leukotriene receptor antagonist that was invented to treat patients with chronic asthma. Methods: To evaluate whether the zafirlukast improved the peak expiratory flow rate (PEFR) and clinical symptoms, 31 asthmatic patients with moderate persistent asthma who received regular inhaled corticosteroid were randomly divided into the study group (N = 17). They received the zafirlukast 20 mg bid for 4 weeks, and the control group (N = 14) received a placebo. Daily morning and evening PEFR and St. George's Respiratory Questionnaire (SGRQ) scoring were recorded respectively. The levels of serum IgE and urine leukotriene E4 before and after treatment were measured using enzyme linked immunosorbent assay and enzyme immunoassay kits. Results: In the zafirlukast treated group, the morning PEFR was significantly improved from 314.4 ± 20.6 to 340.6 ± 18.3 L/min (N = 17, p <0.05) after 4 weeks of treatment, while the control group did not show any significant changes. The zafirlukast group had significant improvement in their symptom scores of SGRQ from 48.6 ± 4.6 to 33.8 ± 4.7 (N = 17, p <0.05). However, the placebo did not improve the symptom scores. Conclusion: Leukotriene receptor antagonists effectively improved symptoms and benefited lung function for moderate persistent asthmatic patients who had received regular treatments with inhaled steroids.

Original languageEnglish
Pages (from-to)554-560
Number of pages7
JournalChang Gung Medical Journal
Volume26
Issue number8
Publication statusPublished - Aug 2003
Externally publishedYes

Fingerprint

Asthma
Peak Expiratory Flow Rate
Steroids
Lung
Leukotriene Antagonists
Placebos
Leukotriene E4
Control Groups
Immunoenzyme Techniques
Immunoglobulin E
Adrenal Cortex Hormones
Therapeutics
Enzyme-Linked Immunosorbent Assay
zafirlukast
Urine
Serum
Surveys and Questionnaires

Keywords

  • Leukotriene
  • Peak expiratory flow rate
  • St George's respiratory questionnaire

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zafirlukast Improves Pulmonary Function in Patients with Moderate Persistent Asthma Receiving Regular Inhaled Steroids : A Prospective Randomized Control Study. / Huang, Chung Jen; Wang, Chun Hua; Liu, Wen Te; Yang, Mei Chen; Lin, Horng Chyuan; Yu, Chih Teng; Shiao, Chia Jung; Tan, Chia Chun; Yang, Chao Kai; Kuo, Han Pin.

In: Chang Gung Medical Journal, Vol. 26, No. 8, 08.2003, p. 554-560.

Research output: Contribution to journalArticle

Huang, Chung Jen ; Wang, Chun Hua ; Liu, Wen Te ; Yang, Mei Chen ; Lin, Horng Chyuan ; Yu, Chih Teng ; Shiao, Chia Jung ; Tan, Chia Chun ; Yang, Chao Kai ; Kuo, Han Pin. / Zafirlukast Improves Pulmonary Function in Patients with Moderate Persistent Asthma Receiving Regular Inhaled Steroids : A Prospective Randomized Control Study. In: Chang Gung Medical Journal. 2003 ; Vol. 26, No. 8. pp. 554-560.
@article{b13d9ea46a484ebcb4ef0f56ad53220b,
title = "Zafirlukast Improves Pulmonary Function in Patients with Moderate Persistent Asthma Receiving Regular Inhaled Steroids: A Prospective Randomized Control Study",
abstract = "Background: Zafirlukast is a leukotriene receptor antagonist that was invented to treat patients with chronic asthma. Methods: To evaluate whether the zafirlukast improved the peak expiratory flow rate (PEFR) and clinical symptoms, 31 asthmatic patients with moderate persistent asthma who received regular inhaled corticosteroid were randomly divided into the study group (N = 17). They received the zafirlukast 20 mg bid for 4 weeks, and the control group (N = 14) received a placebo. Daily morning and evening PEFR and St. George's Respiratory Questionnaire (SGRQ) scoring were recorded respectively. The levels of serum IgE and urine leukotriene E4 before and after treatment were measured using enzyme linked immunosorbent assay and enzyme immunoassay kits. Results: In the zafirlukast treated group, the morning PEFR was significantly improved from 314.4 ± 20.6 to 340.6 ± 18.3 L/min (N = 17, p <0.05) after 4 weeks of treatment, while the control group did not show any significant changes. The zafirlukast group had significant improvement in their symptom scores of SGRQ from 48.6 ± 4.6 to 33.8 ± 4.7 (N = 17, p <0.05). However, the placebo did not improve the symptom scores. Conclusion: Leukotriene receptor antagonists effectively improved symptoms and benefited lung function for moderate persistent asthmatic patients who had received regular treatments with inhaled steroids.",
keywords = "Leukotriene, Peak expiratory flow rate, St George's respiratory questionnaire",
author = "Huang, {Chung Jen} and Wang, {Chun Hua} and Liu, {Wen Te} and Yang, {Mei Chen} and Lin, {Horng Chyuan} and Yu, {Chih Teng} and Shiao, {Chia Jung} and Tan, {Chia Chun} and Yang, {Chao Kai} and Kuo, {Han Pin}",
year = "2003",
month = "8",
language = "English",
volume = "26",
pages = "554--560",
journal = "Chang Gung Medical Journal",
issn = "0255-8270",
publisher = "Chang Gung Medical Journal",
number = "8",

}

TY - JOUR

T1 - Zafirlukast Improves Pulmonary Function in Patients with Moderate Persistent Asthma Receiving Regular Inhaled Steroids

T2 - A Prospective Randomized Control Study

AU - Huang, Chung Jen

AU - Wang, Chun Hua

AU - Liu, Wen Te

AU - Yang, Mei Chen

AU - Lin, Horng Chyuan

AU - Yu, Chih Teng

AU - Shiao, Chia Jung

AU - Tan, Chia Chun

AU - Yang, Chao Kai

AU - Kuo, Han Pin

PY - 2003/8

Y1 - 2003/8

N2 - Background: Zafirlukast is a leukotriene receptor antagonist that was invented to treat patients with chronic asthma. Methods: To evaluate whether the zafirlukast improved the peak expiratory flow rate (PEFR) and clinical symptoms, 31 asthmatic patients with moderate persistent asthma who received regular inhaled corticosteroid were randomly divided into the study group (N = 17). They received the zafirlukast 20 mg bid for 4 weeks, and the control group (N = 14) received a placebo. Daily morning and evening PEFR and St. George's Respiratory Questionnaire (SGRQ) scoring were recorded respectively. The levels of serum IgE and urine leukotriene E4 before and after treatment were measured using enzyme linked immunosorbent assay and enzyme immunoassay kits. Results: In the zafirlukast treated group, the morning PEFR was significantly improved from 314.4 ± 20.6 to 340.6 ± 18.3 L/min (N = 17, p <0.05) after 4 weeks of treatment, while the control group did not show any significant changes. The zafirlukast group had significant improvement in their symptom scores of SGRQ from 48.6 ± 4.6 to 33.8 ± 4.7 (N = 17, p <0.05). However, the placebo did not improve the symptom scores. Conclusion: Leukotriene receptor antagonists effectively improved symptoms and benefited lung function for moderate persistent asthmatic patients who had received regular treatments with inhaled steroids.

AB - Background: Zafirlukast is a leukotriene receptor antagonist that was invented to treat patients with chronic asthma. Methods: To evaluate whether the zafirlukast improved the peak expiratory flow rate (PEFR) and clinical symptoms, 31 asthmatic patients with moderate persistent asthma who received regular inhaled corticosteroid were randomly divided into the study group (N = 17). They received the zafirlukast 20 mg bid for 4 weeks, and the control group (N = 14) received a placebo. Daily morning and evening PEFR and St. George's Respiratory Questionnaire (SGRQ) scoring were recorded respectively. The levels of serum IgE and urine leukotriene E4 before and after treatment were measured using enzyme linked immunosorbent assay and enzyme immunoassay kits. Results: In the zafirlukast treated group, the morning PEFR was significantly improved from 314.4 ± 20.6 to 340.6 ± 18.3 L/min (N = 17, p <0.05) after 4 weeks of treatment, while the control group did not show any significant changes. The zafirlukast group had significant improvement in their symptom scores of SGRQ from 48.6 ± 4.6 to 33.8 ± 4.7 (N = 17, p <0.05). However, the placebo did not improve the symptom scores. Conclusion: Leukotriene receptor antagonists effectively improved symptoms and benefited lung function for moderate persistent asthmatic patients who had received regular treatments with inhaled steroids.

KW - Leukotriene

KW - Peak expiratory flow rate

KW - St George's respiratory questionnaire

UR - http://www.scopus.com/inward/record.url?scp=0142152629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142152629&partnerID=8YFLogxK

M3 - Article

C2 - 14609035

AN - SCOPUS:0142152629

VL - 26

SP - 554

EP - 560

JO - Chang Gung Medical Journal

JF - Chang Gung Medical Journal

SN - 0255-8270

IS - 8

ER -